http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014121221-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e235234938e30561ca942f42a70b52cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
filingDate 2014-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32fc8698a217d2dc2a7c6f7ab7f59951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e6084a82bb0c4f9cef26400ec3c7070
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ef4540ab3c6b5ed0b70bfe95885b83d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ac1062ed42c14ec44f22b9bffb3e064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19575032136459323c9738db6d8bcb5c
publicationDate 2015-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2014121221-A8
titleOfInvention Administration of an anti-activin-a compound to a subject
abstract The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine.The invention further relates to methods of identifying subjects for treatment factors.
priorityDate 2013-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399412
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504160
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953

Total number of triples: 34.